Gene Synthesis Technology and Global Markets Report 2023-2028: Technological Innovations and Implications for Healthcare, Research, and Beyond
May 14, 2024 09:27 ET
|
Research and Markets
Dublin, May 14, 2024 (GLOBE NEWSWIRE) -- The "Gene Synthesis: Technologies and Global Markets 2023-2028" report has been added to ResearchAndMarkets.com's offering.The gene synthesis industry, a...
Immatics Announces First Quarter 2024 Financial Results and Business Update
May 14, 2024 07:00 ET
|
https://immatics.com/
Company Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial with ACTengine® IMA203 TCR-T Targeting PRAME Updated clinical data on ACTengine® IMA203 targeting PRAME in 30 heavily...
Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
May 13, 2024 17:01 ET
|
Turnstone Biologics Corp.
Turnstone Biologics Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
May 13, 2024 16:47 ET
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Global Cell Therapy and Gene Therapy Market Report 2023-2029
May 13, 2024 11:34 ET
|
Research and Markets
Dublin, May 13, 2024 (GLOBE NEWSWIRE) -- The "Cell Therapy and Gene Therapy Markets (Markets by Disease Type), 2023-2029" report has been added to ResearchAndMarkets.com's offering.A newly released...
Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
May 13, 2024 08:15 ET
|
Senti Biosciences, Inc.
Senti Bio today announced that patient dosing has commenced in the Phase 1 clinical trial of SENTI-202.
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
May 09, 2024 16:05 ET
|
Senti Biosciences, Inc.
Senti Biosciences, Inc. (Nasdaq: SNTI) today reported operational updates and financial results for the first quarter of 2024.
Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update
May 09, 2024 16:05 ET
|
Vor Biopharma
On-track for trem-cel and VCAR33ALLO clinical updates in the second half of 2024Trem-cel trial expanded to include patients with myelodysplastic syndromes (MDS); Mylotarg™ dosing has advanced to the...
Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference
May 08, 2024 09:00 ET
|
Turnstone Biologics Corp.
Dr. Sammy Farah, Turnstone's President and CEO, to present at the 2024 Bank of America Securities Health Care Conference in Las Vegas, NV.
Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider
May 06, 2024 06:25 ET
|
GENENTA SCIENCE SPA
MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power...